Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 316

The DOI matches its Crossref record; 55 of the 55 references it cites were found in a registry or an index.

Allosteric and orthosteric pharmacology of cannabidiol and cannabidiol‐dimethylheptyl at the type 1 and type 2 cannabinoid receptors

Open access
Tham, Mylyne, Yilmaz, Orhan, Alaverdashvili, Mariam, Kelly, Melanie E M, Denovan‐Wright, Eileen M, Laprairie, Robert B·2019·British Journal of Pharmacology

Abstract

Background and Purpose: We sought to understand why (−)‐cannabidiol (CBD) and (−)‐cannabidiol‐dimethylheptyl (CBD‐DMH) exhibit distinct pharmacology, despite near identical structures. Experimental Approach: HEK293A cells expressing either human type 1 cannabinoid (CB 1) receptors or CB 2 receptors were treated with CBD or CBD‐DMH with or without the CB 1 and CB 2 receptor agonist CP55,940, CB 1 receptor allosteric modulator Org27569 or CB 2 receptor inverse agonist SR144528. Ligand binding, cAMP levels and βarrestin1 recruitment were measured. CBD and CBD‐DMH binding was simulated with models of human CB 1 or CB 2 receptors, based on the recently published crystal structures of agonist‐bound (5XRA) or antagonist‐bound (5TGZ) human CB 1 receptors. Key Results: At CB 1 receptors, CBD was a negative allosteric modulator (NAM), and CBD‐DMH was a mixed agonist/positive allosteric modulator. CBD and Org27569 shared multiple interacting residues in the antagonist‐bound model of CB 1 receptors (5TGZ) but shared a binding site with CP55,940 in the agonist‐bound model of CB 1 receptors (5XRA). The binding site for CBD‐DMH in the CB 1 receptor models overlapped with CP55,940 and Org27569. At CB 2 receptors, CBD was a partial agonist, and CBD‐DMH was a positive allosteric modulator of cAMP modulation but a NAM of βarrestin1 recruitment. CBD, CP55,940 and SR144528 shared a binding site in the CB 2 receptor models that was separate from CBD‐DMH. Conclusion and Implications: The pharmacological activity of CBD and CBD‐DMH in HEK293A cells and their modelled binding sites at CB 1 and CB 2 receptors may explain their in vivo effects and illuminates the difficulties associated with the development of allosteric modulators for CB 1 and CB 2 receptors. Linked Articles: This article is part of a themed section on 8 th European Workshop on Cannabinoid Research. To view the other articles in this section visit http://onlinelibrary.wiley.com/doi/10.1111/bph.v176.10/issuetoc

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1111/bph.14440

Cites

55 of 55 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

1 retracted

Show all 55 references

Cited by

See all 316

Metadata

Authors
Tham, M., Yilmaz, O., Alaverdashvili, M., Kelly, M. E. M., Denovan‐Wright, E. M., & Laprairie, R. B.
Venue
British Journal of Pharmacology
Publisher
Wiley
Published
2018-08-10
Volume
176
Issue
10
Pages
1455-1469
ISSN
  • 0007-1188 (ISSN-L)
  • 1476-5381
OpenAlex
W2870516394
Cited by
316
References
55
FWCI
18.67
Type
journal article
Language
en
Open access
bronze

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Allosteric and orthosteric pharmacology of cannabidiol and cannabidiol‐dimethylheptyl at the type 1 and type 2 cannabinoid receptors. https://app.cochat.ai/papers/10.1111/bph.14440
The paper
Tham, M., Yilmaz, O., Alaverdashvili, M., Kelly, M. E. M., Denovan‐Wright, E. M., & Laprairie, R. B. (2019). Allosteric and orthosteric pharmacology of cannabidiol and cannabidiol‐dimethylheptyl at the type 1 and type 2 cannabinoid receptors. British Journal of Pharmacology. https://doi.org/10.1111/bph.14440

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.